Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales - Milestone Pharmaceuticals (NASDAQ:MIST
Lucro da Milestone Pharmaceuticals veio abaixo das projeções por $0,43; receita menor do que estimativas
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Milestone Pharmaceuticals (NASDAQ:MIST)